COPD - quick-relief drugs
COPD - quick-relief drugs; Chronic obstructive pulmonary disease - control drugs; Chronic obstructive airways disease - quick-relief drugs; Chronic obstructive lung disease - quick-relief drugs; Chronic bronchitis - quick-relief drugs; Emphysema - quick-relief drugs; Bronchitis - chronic - quick-relief drugs; Chronic respiratory failure - quick-relief drugs; Bronchodilators - COPD - quick-relief drugs; COPD - short-acting beta agonist inhaler
Quick-relief Beta-agonist Inhalers
Quick-relief beta-agonists help you breathe better by relaxing the muscles of your airways. They are short-acting, which means they stay in your system only for a short time.
Some people take them just before exercising. Ask your doctor if you should do this.
If you need to use these drugs more than 3 times a week, or if you use more than one canister a month, your COPD probably is not under control. You should call your doctor.
Kinds of Quick-relief Beta-agonists
Quick-relief beta-agonists inhalers include:
- Albuterol (ProAir HFA; Proventil HFA; Ventolin HFA)
- Levalbuterol (Xopenex HFA)
- Albuterol and ipratropium (Combivent)
Side effects might include:
- Fast or irregular heartbeats. Call your doctor right away if you have this side effect.
Some of these medicines also exist in pills, but the side effects are a lot more significant, so they are very rarely used that way.
Oral steroids (also called corticosteroids) are medicines you take by mouth, as pills, capsules, or liquids. They are not quick-relief medicines, but are often given for 7 to 14 days when your symptoms flare-up. Sometimes you might have to take them for longer.
Oral steroids include:
Anderson B, Brown H, Bruhl E, et al. Institute for Clinical Systems Improvement website. Health Care Guideline: Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD). 10th edition.
Han MK, Lazarus SC. COPD: clinical diagnosis and management. In: Broaddus VC, Mason RJ, Ernst JD, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 6th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 44.
Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931-1940. PMID: 28513453
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report: GOLD Executive Summary. Respirology. 2017;22(3):575-601. PMID: 28150362
Last reviewed on: 2/18/2018
Reviewed by: Denis Hadjiliadis, MD, MHS, Paul F. Harron Jr. Associate Professor of Medicine, Pulmonary, Allergy, and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team. 02-25-19: Editorial update.